QuantumScape Reports Fourth Quarter 2022 Business and Financial Results
SAN JOSE, Calif.–(BUSINESS WIRE)–QuantumScape Corporation (NYSE: QS), a leader in developing next-generation solid-state lithium-metal batteries,…
Year: 2023
Summit Materials, Inc. Reports Fourth Quarter and Full Year 2022 Results
Record Safety Performance Record Annual Organic Pricing Growth for All Lines of Business Record Annual…
Dine Brands Global, Inc. to Host Fourth Quarter and Fiscal 2022 Earnings Conference Call on March 1, 2023
GLENDALE, Calif.–(BUSINESS WIRE)–Dine Brands Global, Inc. (NYSE: DIN), the parent company of Applebee’s Neighborhood Grill…
Lightbeam Health Solutions Announces U.S. Patent for Technology to Monitor Population Health Outcomes and Performance
Patent number 11494724 was issued to Lightbeam by the U.S. Patent and Trademark Office (USPTO)…
Sanofi: Information concerning the total number of voting rights and shares – January 2023
Information concerning the total number of voting rights and shares, provided pursuant to article L….
Li-Bridge Outlines Steps for U.S. to Double Annual Lithium Battery Revenues to $33 Billion and Provide 100,000 Jobs by 2030
CHICAGO–(BUSINESS WIRE)–Li-Bridge, a public-private alliance representing the U.S. battery ecosystem, convened by the U.S. Department…
TrueFort Appoints Scott Schneider Chief Revenue Officer
Microsegmentation Technology Leader Taps Former BitSight Executive to Lead Sales Organization WEEHAWKEN, N.J.–(BUSINESS WIRE)–#Applicationprotection—TrueFort, the…
Rimini Street Selects Tokyo for 2023 $50,000 RMNI LOVE Charitable Grant Program
Company’s self-funded charitable program invites certified charities in Tokyo and nearby regions to apply for…
Hippo Video Secures $8M to Drive Sales Engagement with Personalized Videos at Scale
Powered by generative AI, Hippo Video’s hyper-personalized video content increases sales, productivity, and efficiency for…
Sebset Launches IT & Marketing Solutions for Real Estate Businesses
Sebset provides digital marketing services for real estate professionals, using emerging technology to boost online…
Luke Litteken Named Chair of National Trade Association
Luke Litteken, SVP, Natural Gas Business Unit of Xcel Energy, is the new chair of…
KDDI Uses Wind River Studio for Its Commercial Deployment of 5G Open vRAN Sites in Japan
ALAMEDA, Calif.–(BUSINESS WIRE)–#5g—Wind River®, a global leader in delivering software for mission-critical intelligent systems, today…
ImmuCell to Announce Unaudited Financial Results for the Year Ended December 31, 2022
Conference Call Scheduled for Wednesday, February 22, 2023 at 9:00 AM ET PORTLAND, Maine, Feb….
Nymox Announces NYMOZARFEX Marketing Application is Accepted For Review
IRVINE, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) — Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”)…
Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD
Psycheceutical enters into agreement with iNGENū to conduct human clinical trials of NeuroDirect™ ketamine topical…
Trethera Announces Appointment of Laurent Dubois to Board of Directors
LOS ANGELES, Feb. 15, 2023 (GLOBE NEWSWIRE) — Trethera Corporation (“Trethera”), a clinical-stage biopharmaceutical company…
Entera Bio Announces FDA’s Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis
Type D meeting protocol submission builds on concurrence reached with FDA following successful Type C…
GAIA BioMedicine and TreeFrog Therapeutics Announce Collaboration for the Expansion of Allogeneic NK-like Cells Against Solid Tumors
Gaia Biomedicine & TreeFrog Therapeutics announce collaboration for the expansion of allogeneic NK-like cells against…
Eyenovia Announces Development Collaboration Agreement with Formosa Pharmaceuticals
Collaboration will combine Eyenovia’s Optejet® dispensing technology with Formosa’s APNT™ nanoparticle formulation platform for the…
Junshi Biosciences and Coherus Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
– Final overall survival analysis of the JUPITER-02 trial shows first-line treatment with toripalimab plus…